Ranibizumab 0.5mg Injection$247.00
1–9 boxes
$247.00 each
10–24 boxes
8% off
25+ boxes
10% off
Ranibizumab 0.5mg Injection
SKU GME1322Eye Care
Product Introduction
Ranibizumab 0.5mg is an intravitreal anti-VEGF antibody fragment for selected retinal diseases with abnormal blood-vessel growth or leakage. The 0.3mg and 0.5mg presentations have indication-specific dosing contexts.
How to use
An ophthalmologist administers a precisely measured intravitreal dose under aseptic conditions. The injection interval depends on the retinal diagnosis and response. Eye pressure and retinal status are checked as appropriate.
How it works
Ranibizumab binds VEGF-A and prevents activation of its receptors, reducing abnormal vessel formation and fluid leakage in the retina.
Side effects
Eye discomfort, floaters, conjunctival bleeding and raised eye pressure can occur. Endophthalmitis, retinal detachment and significant intraocular inflammation are serious uncommon risks.
Important information
Active ocular infection or severe intraocular inflammation can preclude injection.
Uses
- Selected wet AMD, retinal-vein-occlusion-related macular oedema, diabetic retinal disease and myopic choroidal neovascularisation under a 0.5mg intravitreal regimen.
Benefits
Suppressing VEGF-related leakage helps preserve retinal function and can improve vision in a responsive eye.
Are 0.3mg and 0.5mg automatically interchangeable?
No. Dose selection depends on the retinal condition and the verified preparation; a different number is not simply a stronger version of the same regimen.
Can I drive myself home after a ranibizumab injection?
Arrange for someone else to drive you home. The injection procedure and pupil-dilating drops can temporarily affect vision, so wait until your sight has returned to normal before driving.
Why can treatment continue after vision improves?
Retinal disease can reactivate, so treatment interval follows examination and imaging rather than symptoms alone.
What symptoms after injection need urgent care?
Increasing pain, light sensitivity, marked redness or a new loss of vision needs same-day eye assessment.
Anti-VEGF: a treatment blocking vascular endothelial growth factor. Choroidal neovascularisation: abnormal vessels beneath the retina. OCT: optical coherence tomography imaging.; AR: Ranibizumab 0.5mg حقن; FR: Ranibizumab 0.5mg injection; PT: Ranibizumab 0.5mg injeção; ES: Ranibizumab 0.5mg inyección; RU: Ranibizumab 0.5mg инъекция; ID: Ranibizumab 0.5mg suntikan; VI: Ranibizumab 0.5mg thuốc tiêm; MS: Ranibizumab 0.5mg suntikan; TL: Ranibizumab 0.5mg iniksyon; ZH-SG: Ranibizumab 0.5mg 注射剂